TikoMed speaks at the NeuroAdvance meeting for the 2:nd year following

oct,, 11, mon,

Time:


I am honored to be invited to appear on the panel of the Neuro Advance Boston meeting for the second time. There is, to my knowledge, no other meeting that assembles such a qualified mix of business and science and where the potential for creating cures is so passionately spoken of. / Adam Bruce Founder and CEO, TikoMed

http://bbbiotechconference.com/conference-details.php?id=62

Neuro Advance Boston is an off-the-record forum that brings together CMOs, CSOs, CEOs, and Heads of Neuro from top biopharmaceutical companies in the neuroscience and pain management space, along with leading academics and healthcare investors, to brainstorm about the most pressing issues facing neuro drug development.

Testimonial from past participant:
”I enjoyed every moment. The format patient and disease centric discussion were just perfect and the attendees were just right and so was also the intimate atmosphere.” – Adam Bruce, Founder, TikoMed

NEURO ADVANCE – OCTOBER 11, 2017 – DRAFT

TimeAgenda
7:00-8:00 amRegistration and Networking Breakfast
8:00-8:30 amWelcome and Opening Remarks
8:30-9:00 amChallenges of CNS Translational Research
Jaswant GiddaCEO, Anagin; Maria MaccecchiniPresident & CEO, QR Pharma; Timothy PiserCSO, Luc Therapeutics; Darryle SchoeppVP & Head, Neuroscience, Merck
9:00-9:30 amFinancing Innovation in Neuroscience
Adam BruceCEO & Founder, TikoMed; Russell HerndonPresident & CEO, Hydra BioSciences; Amir TamizProgram Director, Office of Translational Research, NIH
Moderator: Uli HacksellCEO, Cerecor
9:30-10:00 amNovel Approaches to Alzheimer’s Disease
Larry AltstielCMO, vTv Therapeutics; John HoekmanCEO, Impel Neuropharma; Leen KawasPresident & CEO, M3 Biotechnology; Jonathan LewisCEO, Samus Therapeutics; Kenneth MochPresident & CEO, Cognition Therapeutics
10:00-10:30 amNetworking Break
10:30-11:00 amPartnering in Neuroscience
Ivana Magovcevic-LiebischEVP, Axcella Health; Klaus MendlaGlobal Head, BD&L, CNS, Boehringer Ingelheim; Mark NuttallHead, Immunology & MS BD, Sanofi Genzyme; Cynthia Schwalm, President, North American Commercial Operations, Ipsen; Yaron WerberChief Business & Finanical Officer, Ovid Therapeutics
Moderator: Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche
11:00-11:30 amDigital Advances and Disruptive Innovation in Neuroscience
Ana MaiquesCEO, Neuroelectrics; Eddie MartucciCo-Founder & CEO, Akili Interactive
11:30-12:00 pmAdvances in Neuromodulation, Neurostimulation, & Neurotrauma
Richard ManganoCSO, Relmada Therapeutics; Corey McCannCEO, Pear Therapeutics; Lisa McKerracherCEO, BioAxone bioSciences
Moderator: Elizabeth WooSVP, Flex Pharma
12:00-1:00 pmNetworking Lunch
1:00-1:30 pmRelapsing MS – Developing and Discovering the Possibilities
Marc BeerChairman, Minerva Neurosciences; Florian EichlerDirector, Center for Rare Neurological Diseases, Massachusetts General Hospital; Mike Panzara, Franchise Lead, Neurology, WAVE Life Sciences
Moderator: PJ AnandCEO, Alcyone Life Sciences
1:30-2:00 pmAdvances in Neurodegenerative and Neuromuscular Disorders
Rick Batycky
Chief Technology Officer, Acorda Therapeutics; Paul BolnoPresident & CEO, WAVE Life Sciences; Jesus Martin-Garcia, CEO, GeNeuro; Eric SchaefferSenior Director, Neuroscience External Innovation, Johnson & Johnson
Moderator: Peter LansburyCSO, Lysosomal Therapeutics
2:00-2:30 pmAdvances in Psychiatry
Remy LuthringerPresident & CEO, Minerva Neuroscience; Ron MarcusCMO, Head, Regulatory, Cerecor; Tony McKinneyPresident & CEO, Neurovance; Alex TkachenkoCEO, BlackThorn Therapeutics
Moderator: Elliot EhrichEVP & CMO, Alkermes
2:30-2:50 pmGenetics of Neurology & Psychiatry
Richard GouldGerhard KoenigCEO, Quartet Medicine; Jens WendlandR&D Lead, Nestle Health Science
Moderator: Kiran ReddyVenture Partner, Clarus Ventures
2:50-3:20 pmNetworking Break
3:20-3:40 pmFireside Chat
3:40-4:10 pmAddressing Pain and Addiction
Danguole Altman
President & CEO, Vapogenix; Elliot EhrichEVP, R&D, CMO, Alkermes; Randall StevensCMO, Centrexion
4:10-4:40 pmAdvances in Neuroinflammation
Maurice Zauderer
CEO, Vaccinex
4:40-5:10 pmAdvances in Parkinson’s Disease
Kees BeenCEO, Lysosomal Therapeutics; Jesse CedarbaumVP, Neurology Discovery & Development, Biogen; Spyros PapapetropoulosVP, Neurodegenerative Diseases, Teva; Ken RhodesCSO, Yumanity; Serge StankovicEVP, Head of R&D, ACADIA Pharmaceuticals
4:50-6:00 pmCocktails and Hors d’oeuvres